Illumina, Inc. completes acquisition of Fluent BioSciences to expand single-cell analysis capabilities
Illumina, Inc. completes acquisition of Fluent BioSciences to expand single-cell analysis capabilities
07/09/24, 8:31 PM
Industry
biotechnology
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has acquired Fluent BioSciences, the developer of an emerging and highly differentiated single-cell technology. This acquisition will accelerate Illumina's capabilities in single-cell analysis and discovery, expanding its offerings to a broader customer base.
Company Info
Company info
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:Brian Blanchett858.291.6421 IR@illumina.com
Media:Dr. Karen Birmingham646.355.2111 pr@illumina.com